As shown in Figure 3, higher mean ≥ 3 grade CRS event incidences were observed in the anti-CD19 CAR-T treatment of ALL and NHL, and anti-BCMA CAR-T of MM, which ranged between 25% and 36%. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.